The Technical Analyst
Select Language :
Theratechnologies Inc [THTX]

Exchange: NasdaqCM Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Theratechnologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Theratechnologies Inc is listed at the NASDAQ Exchange

1.40% $2.18

America/New_York / 28 sep 2023 @ 16:00


Theratechnologies Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 52.76 mill
EPS: 0
P/E: 0
Earnings Date: Oct 10, 2023
SharesOutstanding: 24.20 mill
Avg Daily Volume: 0.227 mill
RATING 2023-09-25
B-
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Neutral
DE: Strong Sell
P/E: Strong Sell
Price To Book: Strong Sell
QUARTER GROWTHS
1/222/223/224/221/232/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0 | sector: PE 0
PE RATIO: COMPANY / INDUSTRY
-0.04x
Company: PE 0 | industry: PE 47.78
DISCOUNTED CASH FLOW VALUE
$2.43
(11.49%) $0.250
Date: 2023-09-28
Expected Trading Range (DAY)

$ 1.912 - 2.45

( +/- 12.29%)
ATR Model: 14 days

Forecast: 16:00 - $2.15

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $2.15
Forecast 2: 16:00 - $2.15
Forecast 3: 16:00 - $2.15
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.18 (1.40% )
Volume 0.0501 mill
Avg. Vol. 0.227 mill
% of Avg. Vol 22.05 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Theratechnologies Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Theratechnologies Inc

RSI

Intraday RSI14 chart for Theratechnologies Inc

Last 10 Buy & Sell Signals For THTX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Theratechnologies Inc

THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Last 10 Buy Signals

Date Signal @
ZENUSDSep 28 - 16:16$7.85
ZECUSDSep 28 - 16:16$26.43
YGGUSDSep 28 - 16:16$0.217
XTZUSDSep 28 - 16:16$0.666
FLOWUSDSep 28 - 16:16$0.449
COMPUSDSep 28 - 16:16$48.66
FETUSDSep 28 - 16:16$0.218
DOTUSDSep 28 - 16:16$4.08
DOTUSDSep 28 - 16:16$4.08
YFIUSDSep 28 - 16:15$5 262.77

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.